Shigella Sonnei

Dosage for Shigella Sonnei allergenic extract is highly individualized and must be determined by a qualified allergist or immunologist. There is no 'standard' dose because the product is non-standardized.

• Skin Prick Testing (Epicutaneous): Typically, one drop of the concentrated extract is applied to the skin, followed by a prick or scratch through the drop. Results are read after 15–20 minutes.
• Intradermal Testing: If the prick test is negative, a healthcare provider may inject 0.02 mL to 0.05 mL of a highly diluted extract (e.g., 1:1000 or 1:100 w/v) into the dermis of the forearm.
• Immunotherapy (Maintenance): If used for desensitization, doses usually start extremely low (e.g., 0.1 mL of a 1:100,000 dilution) and are gradually increased over several months to a maintenance dose determined by patient tolerance.

Shigella Sonnei is not routinely approved for pediatric use unless specifically directed by a pediatric allergist. When used in children, the dosage is generally similar to adult diagnostic volumes (0.02 mL for intradermal), but the clinician may choose higher dilutions to minimize the risk of a systemic reaction. Safety and efficacy in infants have not been established.

Renal Impairment

No specific dosage adjustments are provided for patients with renal impairment, as the systemic absorption of the extract is negligible. However, patients with end-stage renal disease may have altered skin reactivity (uremic pruritus or suppressed DTH), which can interfere with test interpretation.

Hepatic Impairment

Hepatic impairment does not typically require a dose adjustment for allergenic extracts. The primary concern is the patient's overall stability and ability to tolerate a potential systemic allergic reaction.

Elderly Patients

Elderly patients may exhibit reduced skin reactivity due to age-related changes in skin turgor and immune senescence. Healthcare providers may need to use positive controls (histamine) more diligently to ensure the validity of the test results.

Shigella Sonnei is administered exclusively by healthcare professionals in a clinical setting equipped to handle emergencies.

• Preparation: The skin (usually the forearm or back) is cleaned with alcohol.
• Administration: The extract is applied via the prick, scratch, or intradermal method.
• Observation: Patients must remain in the medical office for at least 30 minutes following administration to monitor for signs of anaphylaxis.
• Storage: Vials must be stored in a refrigerator between 2°C and 8°C (36°F to 46°F). Do not freeze. Freezing can denature the proteins and render the extract ineffective or unpredictable.

In the context of diagnostic testing, a 'missed dose' simply means the test must be rescheduled. For patients on an immunotherapy schedule, a missed dose may require 'stepping back' to a lower concentration to maintain safety, depending on how much time has elapsed since the last injection. Consult your allergist for a specific catch-up schedule.

An 'overdose' in the context of allergenic extracts usually refers to the administration of a concentration higher than the patient can tolerate, or an accidental intravascular injection.

• Signs: Rapid onset of hives, swelling of the throat (laryngeal edema), wheezing, hypotension (low blood pressure), and loss of consciousness.
• Emergency Measures: Immediate administration of epinephrine (1:1000) intramuscularly, followed by antihistamines, corticosteroids, and fluid resuscitation as needed. Seek emergency medical care immediately if these symptoms occur.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to self-administer these extracts without medical guidance.

Most patients receiving Shigella Sonnei for diagnostic purposes will experience local reactions at the site of administration. These are generally expected and indicate the test is working.

• Local Erythema: Redness at the injection or prick site. This usually appears within minutes and fades within a few hours.
• Pruritus: Itching at the site, which can be intense but is typically localized.
• Wheal Formation: A raised, pale bump that looks like a mosquito bite. This is the primary measurement used to determine a 'positive' test result.

• Delayed Local Swelling: Some patients develop a large area of swelling and redness 4 to 24 hours after the test. This is known as a 'late-phase reaction' and can be uncomfortable but is rarely dangerous.
• Induration: A hardening of the skin at the injection site, more common in intradermal testing.
• Mild Fatigue: Some patients report feeling tired or 'under the weather' for the remainder of the day after receiving multiple skin tests.

• Lymphangitis: Inflammation of the lymphatic vessels leading away from the injection site, appearing as red streaks.
• Fever and Malaise: A systemic 'flu-like' feeling that may occur if a patient is highly sensitive to the bacterial antigens.
• Persistent Granuloma: In very rare cases, a small, hard knot may form under the skin at the injection site and persist for several weeks.

> Warning: Stop taking Shigella Sonnei and call your doctor immediately if you experience any of these symptoms of a systemic allergic reaction (anaphylaxis).

• Respiratory Distress: Sudden shortness of breath, wheezing, or a feeling of 'tightness' in the chest.
• Angioedema: Swelling of the lips, tongue, or throat that may make swallowing or breathing difficult.
• Generalized Urticaria: Hives that spread across the entire body, away from the injection site.
• Hypotension: A sudden drop in blood pressure, characterized by dizziness, lightheadedness, or fainting.
• Tachycardia: A rapid or pounding heartbeat.
• Cyanosis: A bluish tint to the lips or fingernails, indicating poor oxygenation.

Because Shigella Sonnei is typically used for episodic diagnostic testing, long-term side effects are rare. However, repeated exposure through immunotherapy could theoretically lead to:

• Increased Sensitivity: The patient may become more reactive to the antigen over time.
• Chronic Local Changes: Rare instances of skin thinning or pigmentation changes at frequent injection sites.

While specific 'Black Box' labels vary by manufacturer, most non-standardized allergenic extracts carry a general warning regarding Anaphylaxis.

Summary of Warning: This product can cause severe, life-threatening systemic allergic reactions, including anaphylaxis. It must only be administered by physicians who are exceptionally experienced in the treatment of anaphylaxis and the management of respiratory emergencies. Patients must be observed for at least 30 minutes. Patients with unstable asthma are at a significantly higher risk for fatal reactions.

Report any unusual symptoms to your healthcare provider immediately. Even a 'mild' systemic reaction (like itching on the palms of the hands) can be a precursor to a severe event.

Shigella Sonnei allergenic extract is a potent biological substance. It is not intended for self-administration. Every patient must undergo a thorough medical history screening before administration to identify risk factors for severe reactions. Patients should be informed that skin testing is a diagnostic procedure and not a treatment for an active infection.

No specific FDA black box warning exists uniquely for Shigella Sonnei, but it falls under the class-wide warning for all Allergenic Extracts. The primary risk is sudden, severe anaphylaxis. Clinicians must have an 'Emergency Kit' ready, containing at least:

• Epinephrine 1:1000
• Oxygen and airway management tools
• Intravenous fluids
• Antihistamines and injectable corticosteroids.

• Allergic Reactions / Anaphylaxis Risk: The risk is highest in patients with a history of severe asthma or those who have had previous systemic reactions to other microbial antigens.
• Asthma Status: Patients experiencing an acute asthma exacerbation should not undergo skin testing until their condition is stabilized. Reduced pulmonary function (FEV1 < 70% of predicted) is a major risk factor for a poor outcome if a systemic reaction occurs.
• Autoimmune Disorders: Patients with active autoimmune diseases may have unpredictable immune responses to the extract.
• Infection: Do not administer if the patient has an active fever or a systemic infection, as this can complicate the interpretation of the test and potentially worsen the patient's condition.

• Pre-test Assessment: Vital signs (blood pressure, heart rate, and sometimes peak flow for asthmatics) should be checked before administration.
• Post-test Observation: The patient must be visually monitored for 30 minutes. The injection site should be checked for excessive local swelling.
• Lab Tests: No routine blood work is required for the administration of the extract itself, though IgE levels (RAST/ImmunoCAP) may be checked concurrently to correlate with skin test results.

Shigella Sonnei generally does not affect the ability to drive. However, if a patient experiences a systemic reaction or is given antihistamines/epinephrine to treat a reaction, they should not drive or operate machinery until they are fully recovered and cleared by a physician.

There is no direct interaction between alcohol and Shigella Sonnei. However, alcohol consumption can cause vasodilation, which might theoretically increase the rate of absorption of the extract or worsen the symptoms of a 'flare' reaction. It is advisable to avoid alcohol for 24 hours following the test.

If a patient experiences a systemic reaction, the use of that specific extract should be discontinued immediately. Future testing with related antigens must be approached with extreme caution, often requiring higher dilutions or alternative diagnostic methods (such as in vitro blood tests).

> Important: Discuss all your medical conditions with your healthcare provider before starting Shigella Sonnei. Ensure your doctor knows if you are taking any heart medications or have a history of breathing problems.

• Beta-Blockers (e.g., Propranolol, Metoprolol): These medications are generally contraindicated or used with extreme caution during allergenic extract administration. Beta-blockers can make a patient resistant to the effects of epinephrine, which is the primary treatment for anaphylaxis. If a patient on a beta-blocker has a severe reaction, it may be life-threatening and difficult to reverse.
• MAO Inhibitors (e.g., Phenelzine): These can potentiate the effects of sympathomimetics (like epinephrine) used to treat reactions, leading to hypertensive crises.

• ACE Inhibitors (e.g., Lisinopril): Some studies suggest that patients on ACE inhibitors may be at a higher risk for more severe systemic reactions to allergenic extracts or may have a more difficult recovery from anaphylaxis.
• Tricyclic Antidepressants (e.g., Amitriptyline): These can interfere with skin test results (suppressing the wheal and flare) and may also interact with emergency medications.

• Antihistamines (e.g., Loratadine, Cetirizine, Diphenhydramine): These drugs directly block the H1 receptors that cause the 'wheal and flare.' Patients must typically stop taking antihistamines for 3 to 7 days before testing to ensure accurate results.
• H2 Blockers (e.g., Famotidine): While less potent than H1 blockers, they can still partially suppress the skin's response to the extract.
• Topical Corticosteroids: If applied to the test site, they will suppress the local inflammatory response and lead to a false-negative result.

• High-Histamine Foods: Consuming foods high in histamine (aged cheeses, fermented foods) shortly before a test might theoretically increase skin reactivity, though this is rarely clinically significant.
• Caffeine: High doses of caffeine may slightly increase heart rate, which could complicate the monitoring of a patient during a systemic reaction.

• St. John's Wort: May have minor interactions with the immune response or emergency medications.
• Licorice Root: Can have corticosteroid-like effects that might theoretically dampen the skin test response if consumed in large quantities.

• Skin Tests: The administration of Shigella Sonnei will obviously interfere with any other skin tests being performed simultaneously if the sites are too close together (cross-contamination of the wheal/flare).
• In Vitro IgE Tests: The extract itself does not usually interfere with blood tests like RAST, but the immune response triggered by the extract could cause a transient rise in total IgE levels in highly sensitive individuals.

For each major interaction, the mechanism usually involves either the suppression of the allergic response (leading to false negatives) or the interference with the body's ability to respond to emergency treatment (increasing the risk of death from anaphylaxis).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for blood pressure or depression.

Shigella Sonnei must NEVER be used in the following circumstances:

• Previous Anaphylaxis to this Extract: If a patient has had a life-threatening reaction to Shigella Sonnei or any of its components (including preservatives like phenol), they must not receive it again.
• Severe, Uncontrolled Asthma: Patients with a Forced Expiratory Volume in 1 second (FEV1) of less than 70% of their predicted value are at an unacceptably high risk for fatal bronchospasm during a systemic reaction.
• Acute Infection: Patients with an active, high-grade fever or systemic illness should not be tested, as the immune system is already stressed.

Conditions requiring a careful risk-benefit analysis include:

• Pregnancy: While not an absolute contraindication, the risk of inducing anaphylaxis (which can cause fetal hypoxia) usually outweighs the benefit of diagnostic testing during pregnancy.
• Beta-Blocker Therapy: As mentioned, this makes treating a reaction much harder. Doctors must decide if the diagnostic information is worth the increased safety risk.
• Severe Atopic Dermatitis: If the skin is extensively damaged or inflamed, there may be no 'clear' skin available for testing, and the results will be unreliable.

Patients who are highly allergic to other members of the Enterobacteriaceae family or certain fungal species (due to the EPC classification) may show cross-reactivity. If a patient is known to be hypersensitive to related bacterial antigens, the starting dose for Shigella Sonnei should be significantly reduced.

> Important: Your healthcare provider will evaluate your complete medical history, including your current lung function and heart health, before prescribing or administering Shigella Sonnei.

Shigella Sonnei is classified in FDA Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether the extract can cause fetal harm or affect reproduction capacity.

• Risks: The primary danger is not the extract itself, but the potential for maternal anaphylaxis. Anaphylaxis leads to maternal hypotension and respiratory distress, which can cause immediate and severe oxygen deprivation (hypoxia) to the fetus.
• Clinical Recommendation: Most allergists recommend postponing diagnostic skin testing and starting immunotherapy until after delivery. If the patient is already on a stable maintenance dose of immunotherapy, it may be continued with caution, but doses are typically not increased during pregnancy.

It is not known whether the components of Shigella Sonnei extract are excreted in human milk. Because the antigens are proteins that are likely digested in the infant's gut if they were present, the risk to a nursing infant is considered low. However, the mother should be monitored closely for reactions, as a severe reaction could interfere with her ability to breastfeed.

• Approved Use: While children can undergo skin testing, the safety of Shigella Sonnei in very young children (under age 5) is not well-documented.
• Considerations: Children may be more distressed by the testing procedure, and their smaller body mass means that a systemic reaction could progress more rapidly. Dosing is generally based on the same volume as adults but requires even more vigilant observation.

• Skin Reactivity: Patients over age 65 often have thinner skin and a less robust immune response, which can lead to smaller wheal sizes. This may result in 'false negatives' if the clinician is not experienced in geriatric immunology.
• Comorbidities: Elderly patients are more likely to have cardiovascular disease or be taking beta-blockers, both of which increase the danger of a systemic reaction.

In patients with chronic kidney disease, the skin may be hyper-reactive (uremic pruritus) or hypo-reactive. While no dose adjustment is needed for the extract itself, the interpretation of the skin test must be done with caution. Dialysis does not clear the antigens from the skin site.

There are no specific guidelines for hepatic impairment. The main clinical focus remains on the patient's general health and the absence of any clotting disorders that might cause excessive bleeding at the injection site.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or are currently nursing.

Shigella Sonnei allergenic extract acts as a source of exogenous antigens. Upon introduction into the skin, these antigens (primarily proteins and lipopolysaccharides) cross-link specific IgE antibodies on the surface of sensitized mast cells. This cross-linking activates the high-affinity IgE receptor (FcεRI), triggering a signaling cascade involving tyrosine kinases. This results in the rapid release of pre-formed mediators (histamine, proteases) and the de novo synthesis of lipid mediators (leukotrienes). The physiological result is the 'wheal and flare' reaction used for diagnosis.

• Onset of Action: The immediate hypersensitivity reaction (Type I) typically begins within 5 minutes and peaks at 15–20 minutes.
• Duration of Effect: The visible wheal usually resolves within 1 to 2 hours, though a late-phase reaction (Type IV or modified Type I) can occur 4 to 12 hours later.
• Tolerance: Repeated exposure through immunotherapy can induce the production of 'blocking' IgG4 antibodies and promote T-regulatory cell activity, eventually leading to clinical desensitization.

| Parameter | Value |

|---|---|

| Bioavailability | Negligible (Local administration) |

| Protein Binding | N/A (Biological extract) |

| Half-life | Local degradation over 24-48 hours |

| Tmax | 15–20 minutes (for skin reaction) |

| Metabolism | Proteolysis at the injection site |

| Excretion | Lymphatic clearance |

• Molecular Nature: A complex mixture of proteins, glycoproteins, and polysaccharides derived from Shigella sonnei cells.
• Solubility: Soluble in aqueous solutions; often contains 50% glycerin for stability in prick test formulations.
• Preservatives: Typically contains 0.4% phenol to maintain sterility.

Shigella Sonnei is categorized as a Non-Standardized Fungal Allergenic Extract [EPC]. It is related to other microbial extracts like Candida albicans or Trichophyton extracts, which are used similarly in immunological profiling.